ORLANDO, Fla.--(BUSINESS WIRE)--Materialise NV (NASDAQ:MTLS), is proud to announce the launch of the Materialise Mimics Care Suite, a full suite of software and solutions for 3D printing within hospitals. The Materialise Mimics Care Suite is an open and flexible platform that includes planning and design software tools, 3D printed anatomical models and surgical guides, and patient-specific implants. Launched during AAOS, the American Association of Orthopaedic Surgeon’s Annual Meeting, the Suite also introduces Materialise Mimics inPrint, a new software solution that enables surgeons to create accurate medical models for 3D printing in hospitals without the need of advanced clinical engineering support.
With the Materialise Mimics Care Suite, Materialise brings together medical software and services, both established and new, into a single, neutral platform that facilitates the further integration of 3D planning and printing into hospitals. For example, Materialise Mimics inPrint allows clinicians to 3D print in hospitals by connecting data from all modern imaging systems to the ever expanding range of 3D printers on the market. The Materialise Mimics Care Suite also includes software for predictive planning and communication; patient-specific guides that transfer a co-created surgical plan to the OR; and patient-specific models and implants that enable surgeons to treat complex cases.
Materialise Founder and CEO, Wilfried Vancraen, states, “For more than 25 years, we at Materialise have been identifying meaningful applications of 3D printing and developing the backbone of software and solutions needed to successfully bring them to market. We see incredible potential for 3D printing in hospitals, but have also recognized that many existing solutions have slowed adoption of the technology. Therefore, we have developed the Materialise Mimics Care Suite with the aim of helping hospitals better integrate 3D printing and begin unleashing the benefits it offers, which include potential cost savings and patient care improvement.”
Since their foundation, Materialise has been providing leading-edge, 3D visualization and printing solutions to their extensive list of hospital, academic and medical device customers. Materialise’s open and flexible platform of software and services forms the foundation of certified medical 3D Printing, in clinical as well as research environments, enabling medical professionals to revolutionize patient treatment and make the world a better and healthier place.
Materialise incorporates more than 25 years of 3D printing experience into a range of software solutions and 3D printing services, which together form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines the largest group of software developers in the industry with one of the largest 3D printing facilities in the world. For additional information, please visit: www.materialise.com.
About Materialise’s Medical Division
Materialise Medical, which has pioneered many of the leading medical applications of 3D printing, enables researchers, engineers and clinicians to revolutionize innovative patient-specific treatment that helps improve and save lives. Materialise Medical’s open and flexible platform of software and services, Materialise Mimics, form the foundation of certified Medical 3D Printing, in clinical as well as research environments, offering virtual planning software tools, 3D-printed anatomical models, and patient-specific surgical guides and implants. For additional information, please visit: http://hospital.materialise.com/
Cautionary Statement on Forward-Looking Statements
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements relating to, among other things, our planned commercialization efforts and regulatory approvals of our technologies as well as the success thereof and our research and development projects. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control that may cause our actual results to differ materially from our expectations. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.